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Abstract
Background: Homeobox genes murine Rhox5 and human RHOXF1 are expressed in early embryonic stages and
then mostly restricted to germline tissues in normal adult, yet they are aberrantly expressed in cancer cells in vitro
and in vivo . Here we study the epigenetic regulation and potential functions of Rhox5 gene.
Findings: In Rhox5 -silenced or extremely low expresser cells, we observed low levels of active histone epigenetic
marks (H3ac, H4ac and H3K4me2) and high levels of repressive mark H3K9me2 along with DNA hypermethylation
in the promoter. In Rhox5 low expresser cells, we typically observed modest levels of both active and repressive
histone marks along with moderate DNA methylation. In Rhox5 highly expressed CT26 cancer cells, we observed
DNA hypomethylation along with high levels of both active and repressive histone marks. Epigenetic drugs
(retinoic acid and MS-275) induced F9 cell differentiation with enhanced Rhox5 expression and dynamic changes of
epigenetic marks. Finally, Rhox5 knockdown by small hairpin RNA (shRNA) in CT26 colon cancer decreased cell
proliferation and migration in vitro and tumor growth in vivo .
Conclusions: Both DNA methylation and histone methylation/acetylation play key roles in modulating Rhox5
expression in various cell types. The stem cell-like “bivalent domain”, an epigenetic feature originally identified in
key differentiation genes within stem cells, exists in the Rhox5 gene promoter in not only embryonic stem cells but
also cancer cells, cancer stem cells, and differentiated Sertoli cells. As Ras signaling-dependent Rhox5 expression
promotes tumor growth, Rhox5 may be an ideal target for therapeutic intervention in cancer.
Background
The reproductive homeobox on X-chromosome (Rhox )
gene cluster in mouse contains 33 known genes [1], and
three members of this gene family (Rhox2, Rhox4b and
Rhox5 ) are crucial for self-renewal and differentiation
of embryonic stem (ES) cells [2-4]. The founding mem-
ber of Rhox gene cluster, Rhox5 (formerly pem),i s
expressed in early embryos and ES cells [5-7], embryo-
nic carcinoma (EC) cells, and primordial and pre-muscle
stem cells [8]. Intriguingly, Rhox5 is predominantly
expressed in female blastocysts from the paternally
inherited X chromosome [7], yet the paternal copy is
silent in placenta cells [9]. In adult mice, Rhox5 expres-
sion is restricted to germline tissues in both male and
female and is silenced in most somatic tissues [1,10,11].
Rhox5 is expressed from its two promoters, a distal pro-
moter (Pd) and a proximal promoter (Pp), that give rise
to transcripts with different 5’-ends encoding the same
protein. The transcription from Pp depends on both
androgen receptor and androgen [10]. Rhox5 plays an
essential role in self-renewal and differentiation of ES
cells. It has been shown that Rhox5 over-expression is
able to maintain murine ES cells in a pluripotent state
in a leukemia inhibitory factor-independent manner [6],
and can also block ES cell differentiation [3,11]. It pro-
motes differentiation and survival of germ cells in germ-
line tissues [10]. Targeted disruption of Rhox5 increases
male germ cell apoptosis and reduces sperm production,
sperm motility, and fertility [12].
Rhox5 is expressed not only in established cancer cell
lines [13-15], but also in cancers in vivo,e . g . ,a d e n o m a s
and carcinomas in the APC
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expressing K-ras (V12) [16,17]. The Pd promoter was
regarded as the promoter directing the aberrant expres-
sion in tumor cells [10].
Rhox5 may exert important functions in cancer based
on the following evidence. First, partners for Rhox5
include: menin, a tumor suppressor [18], prosaposin, a
multifunctional protein [19], and the cell division cycle
37 (Cdc37) homolog protein [20]. Second, Rhox5 also
mediates transcriptional repression of the netrin-1
receptor gene Unc5c, a tumor suppressor in colorectal
cancer [21]. Third, Rhox5 gene Pd activity in tumor cells
requires Ras signaling [22]. Fourth, in a colon adenoma
model induced by conditional activation of K-ras
V12 in
Msh2 knockout mice, Rhox5 is one of three genes signif-
icantly up-regulated [17]. Finally, Rhox5 renders tumor
cells resistant to apoptotic cell death induced by antic-
ancer therapies [23]. In addition, it may play a role in
cancer initiating cells (or cancer stem [CS] cells) [24].
CS cells are cancer cells that possess characteristics
associated with normal stem cells. They have the ability
to give rise to all cell types found in a particular tumor.
It is possible that ES and CS cells share some key
regulatory genes that are tightly regulated by similar
epigenetic mechanisms.
While there are a total of 33 known Rhox genes clus-
tered in the X chromosome in mouse [1], only two
RHOX genes have been characterized in humans:
RHOXF1 (originally called OTEX and hPEPP1) and
RHOXF2A (originally hPEPP2) [25,26]. While there is
no human homolog of mouse Rhox5,h u m a nRHOXF1
is closest to murine Rhox5 in terms of chromosomal
location of the gene, tissue expression profiles, and
potential functions. RHOXF1 is expressed at relatively
high levels in human ES cells and adult germline stem
cells [27]. It is expressed in human colorectal cancer
and testicular seminoma in vivo [28,29], as well as in
some cancer cell lines [15,26]. Therefore, it is possible
that Rhox5 and RhoxF1 may have comparable functions
despite low sequence conservation and therefore they
may be considered orthologues.
DNA methylation regulates gene expression in normal
mammalian development [30,31]. In cancer, aberrant
promoter hypermethylation plays a major role in tran-
scriptional silencing of critical growth regulators such as
tumor suppressor genes [32,33], while aberrant promo-
ter hypomethylation upregulates germline genes (such
as Rhox5 ) that are normally expressed in embryo stages
and stem cells yet silenced in all or most somatic tissues
[34,35]. Histone modifications together with DNA
methylation in the chromatin regulate many regulatory
genes [36,37]. All known acetylations of histones are
correlated with transcriptional activation [38]. Histone
methylations at lysine and arginine residues are
another class of epigenetic marks [39,40]. A recent high-
resolution profiling study in the human genome indi-
cated that H3K4 trimethylation and the monomethyla-
tions of H3K9, H3K27, H3K79, H4K20 and H2BK5 are
linked to gene activation, whereas trimethylations of
H3K27, H3K9 and H3K79 are linked to repression [40].
In addition, a “bivalent domain” (repressive mark
H3K27me3 and permissive mark H3K4me2/me3) marks
key developmental genes in ES cells [41,42]. This
chromatin bivalent domain in stem/progenitor cells pre-
disposes tumor suppressor genes to DNA hypermethyla-
tion and heritable silencing [43-45].
RHOX5 may be regulated by epigenetic mechanisms.
First, DNA methylation regulates long-range silencing of
Rhox gene cluster including Rhox5 during the post-
implantation development of mice [46]. Second, Rhox5
could be upregulated in ES cells and embryonic fibro-
blast cells by inactivation of DNA methyltransferase
genes [46,47], or in ES cells null for linker histone H1
[48]. While this paper was under revision, Wilkinson,
MacLean, and coworkers showed that the Rhox gene
cluster is imprinted and regulated by histone H1 and
DNA methylation in ES cells [9]. Third, Rhox5 is one of
the X-linked cancer-germline (CG) genes, many of
which are regulated by DNA methylation [14,35,49].
Finally, we have demonstrated that epigenetic drugs
could upregulate Rhox5 in cancer cells through enrich-
ment of active histone marks in the promoter region
preferentially with DNA demethylation [15].
We and our collaborators have previously investigated
epigenetic regulation of genes in normal development
and cancer [15,35,50-52]. In this study, we have con-
firmed that Rhox5 is expressed in ES cells, EC cells, and
cancer cells. We found that Rhox5 is expressed in side
population (SP) cells that enrich for cancer stem/pro-
genitor cells. We have examined the epigenetic marks in
the promoter region, including both DNA methylation
and histone acetylation (H3ac, H4ac and H3K9ac) and
methylation (H3K4me2, H3K9me2 and H3K27me3), and
related them to levels of expression in various cells
types. We showed that epigenetic drugs could induce
differentiation of F9 teratocarcinoma cells, but not SP
cells, with Rhox5 upregulation and concurrent epigenetic
changes. Finally, we demonstrated that Rhox5 gene
knockdown by small hairpin RNA (shRNA) in CT26
colon cancer cells resulted in reduced tumor cell migra-
tion and cell proliferation in vitro and attenuated tumor
growth in vivo .
Results
Expression of Rhox5 gene in ES cells, somatic cells and
cancer cells
Rhox5 gene transcription is controlled by dual promo-
ters, Pd and Pp, producing mRNAs with different 5’
Li et al. Molecular Cancer 2011, 10:63
http://www.molecular-cancer.com/content/10/1/63
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initially examined Rhox5 expression in cancer cells as
well as in ES cells and germline tissues. As shown in
Table 1, Rhox5 mRNA was detected in all 26 cancer cell
lines tested. These cancer lines were derived from 12
different tissues. Two cancer cell lines (EMT6 and
P815) generated faint bands after 35 cycles of PCR fol-
lowing reverse transcription (RT) (Figure 1B). In con-
trast, another cancer-germline gene, P1A, which we
studied previously, was expressed in a much smaller
fraction of cancer cell lines. We then quantified Rhox5
mRNA from representative tissues or cells by RT-qPCR
(Figure 1C). Testis tissue expressing Rhox5 mRNA was
utilized as a positive control. ES and F9 EC cells
expressed low levels of Rhox5 mRNA. Normal somatic
cells such as mononucleocytes (MNC) did not express
Rhox5 mRNA. Rhox5 expression in cancer cells varied
over a wide range, with high levels in CT26 and MC38
cells and extremely low levels in EMT6 and P815 cells.
We next analyzed promoter-specific transcription
from both Pd and Pp of Rhox5 gene in selected normal
cells and cancer cells by promoter-specific RT-PCR as
described previously [15]. As shown in Figure 1D, testis
tissue utilized both Pd and Pp for transcription, while
ES cells utilized the Pd promoter for transcription. TM4
Sertoli cells utilized mainly Pd, consistent with results
from a previous study [53]. Among the selected group
of cancer cells, CT26, MC38, and 4T1 cells utilized both
Pd and Pp for transcription. Rhox5 mRNA was barely
detectable in EMT6 and P815 cells.
We further confirmed gene expression at the protein
level by Western blot analysis (Figure 1E). Both
Figure 1 Rhox5 expression in ES cells, somatic cells and cancer cells. (A). Schematic presentation of the Pd and Pp promoter regions of the
Rhox5 gene. Vertical bars represent CpG dinucletides and open and filled boxes indicated non-coding and coding exons. Three segments (BS-1,
BS-2, BS-3) covering CpG dinucleotides subject to bisulfite sequencing and corresponding regions for ChIP assay (ChIP-1 and ChIP-2) were also
indicated. (B). Rhox5 mRNA in representative cancer cell lines was detected by semi-quantitative RT-PCR. M: PCR marker. (C). Relative Rhox5
mRNA levels as normalized to 1.0E4 copies of GAPDH mRNA. Real-time RT-PCR was performed in triplicates and data from multiple experiments
are presented as mean +/- s.d. The data for ES cells were obtained from single RT-PCR in triplicates. (D). Transcripts from either Pd or Pp were
determined by promoter-specific RT-PCR. Lane M: DNA MW Markers; T: testis; H2 O: water instead of RNA was used in RT. (E). Western blot
analysis of Rhox5 in germline tissues and representative cancer cell lines.
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cells expressed Rhox5 protein (~30 kDa). In contrast,
Rhox5 protein was below the level of detection in
EMT6 and P815 cancer cells. These results were consis-
tent with those obtained by RT-PCR.
RHOXF1 expression in human primary colorectal cancers
We wished to confirm if RHOXF1 is expressed in
human colorectal cancers, as reported by gene expres-
sion profiling [28]. We collected eight matched sets of
specimens from patients with metastatic colorectal can-
cer. These tissues represented liver metastasis and
matched normal liver tissues from eight patients. Total
RNA was purified from these tissues, and the amounts
of RHOXF1 mRNA were quantified by RT-qPCR (Figure
2). RHOXF1 mRNA was expressed in the normal liver
tissues (N), ranging from 122 to 558 copies relative to
1.0E6 copies of b-actin mRNA. In the tumor tissues (T),
RHOXF1 mRNA was also expressed in 7 out of 8
patients, ranging from 15 to 310 copies of mRNA.
Correlation of Rhox 5 gene expression to the histone
epigenetic marks in the promoter region of the gene
We sought to find a correlation between Rhox5 gene
expression and its epigenetic marks in the promoter
region (Table 2). Initially we examined histone modifica-
tions in ES and other cells by ChIP assays. In ES cells,
there was a low level of H3K4me2 and higher levels of
H3K27me3 and H3K9me2 marks on ChIP-1 region (Fig-
ure 3A). In Pd region (ChIP-2 region), the pattern was
similar. This pattern of histone marks would correlate
with the low level of expression seen in ES cells. In
g e n e - s i l e n c e dM N Ca n dm a mmary epithelial cells, as
well as P815 cancer cells with extremely low level of
Rhox5 mRNA, they revealed high levels of H3K9me2
together with low levels of H3K27me3. The active
marks were either undetectable or barely detectable
(Figure 3A and Additional File 1). Interestingly, we did
not detect H3K4me2, H3K27me3, and H3K9me2 marks
on Rhox5 Pd region in 4T1 cells, although a low level of
mRNA was transcribed from Pd in these cells (Addi-
tional File 1).
We chose to compare the histone marks in two cancer
cell lines with either the highest (CT26) or the lowest
(EMT6) Rhox5 expression (Figure 3B & C). The active
marks (H3ac, H4ac, H3K9ac and H3K4me2) are high in
CT26 cells, and very low in EMT6 cells. Interestingly,
we detected relative high levels of repressive marks
(H3K9me2 and H3K27me3) in both CT26 and EMT6
cells.
We have also paid attention to the “bivalent domain”
chromatin structure in the promoter region. The H3
K4me2 and K27me3 bivalent marks exist not only in
undifferentiated ES cells, but also in germline-tissue
derived somatic cells (TM4) and some cancer cells
(MOSEC, CT26 and MC38).
Strong correlation of promoter DNA methylation with
Rhox 5 gene expression
We wished to determine DNA methylation status in the
promoters of Rhox5 gene in the same set of cell types.
Both Pd and Pp promoters of the gene are CpG-poor
and contain no CpG islands (GenBank accession:
AF410462) [54]. Specific primers were selected to
amplify bisulfite-treated genomic DNA from ten lines of
cells including ES cells, somatic cells, and cancer cells.
These primers covered DNA segments in the Pd, Pp,
and translation start site (TSS) regions (BS-1, BS-2 and
BS-3 regions, respectively), covering four CpG dinucleo-
tides each (see Figure 1A). As shown in Figure 4 (A &
B), both ChIP-1 (Pd) and TSS regions were relatively
hypermethylated in ES cells. As Rhox5 is expressed at a
low level from Pd in ES cells, our results suggested that
DNA hypermethylation and a moderately repressive pat-
tern of histone epigenetic marks together dictated a low
level of Rhox5 expression. TM4 and MOSEC cells had
similar epigenetic patterns as ES cells, and this also cor-
related with low level of Rhox5 expression. For CT26
and MC38 cells that express high levels of Rhox5 gene,
hypomethylated DNA was found in the promoter
regions. Data from additional normal and cancer cells
were presented in Additional File 2. The percentage of
CpG methylation in the Pd region correlated quite
well with the levels of Pd mRNA expression in the cells
(Figure 4B).
Table 1 Rhox5 and P1A mRNA expression in mouse
cancer cells
Tumor
type
Cell
line
Rhox5 P1A Tumor type Cell
line
Rhox5 P1A
Mammary 4T1 + - Lung LLC + -
C3-L5 + - LM2 + -
C127I + - M109 + -
EMT6 +/- - Fibrosarcoma MCA102 + -
MM2MT + - MCA205 + -
TS/A + - Hepatoma Hepa1-6 + -/+
TUBO + - Lymphoma A20 + +
Colorectal CA07/A + - EL4 + +
CA51 + + Mastocytoma P815 -/+ +
CMT93 + - Melanoma B16 + -
CT26 + - Ovarian MOSEC + -
MC38 + - Pancreatic Panc02 + -
Leukemia L1210 + - EC F9 + +
* Footnote: “+” represents a strong while “-/+” very weak and “-” undetectable
signals of cDNA amplification after 35 cycles of PCR following reverse
transcription (RT). The status of P1A expression in some cancer cell lines has
been reported in our previous study [35].
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agents resulted in significant changes of histone marks
A distinct characteristic of genes marked by a bivalent
domain is that these genes can change expression levels
rapidly during ES differentiation as bivalent marks are
resolved to monovalent marks (H3K4me2 or H3K27me3
only), remain bivalent, or disappear altogether
[41,42,55]. As a result we sought to study changing pat-
terns of histone epigenetic marks during EC differentia-
tion. The F9 EC cells can be induced to differentiate
with upregulation of Rhox5 mRNA by retinoic acid
(RA), RA plus cAMP, or valproic acid. All these agents
exhibit properties of epigenetic modulators [8,56,57].
The HDAC inhibitor MS-275 can induce p21-dependent
growth arrest and differentiation of human leukemia
cells at lower doses [58]. We demonstrated that both
MS-275 and RA treatment induced Rhox5 mRNA 3-fold
by 72 h, and RA plus cAMP could induce Rhox5 20-25-
fold in 5 days (Figure 5A). These differentiated cells dis-
played dramatically reduced tumorigenicity in nude
mice (Additional File 3). In undifferentiated F9 EC cells,
the Pd promoter was marked with low levels of K4me2,
Figure 2 RhoxF1 mRNA expression in liver lesions of colorectal cancer and matched liver tissues from colorectal cancer patients. Total
RNA from matched liver tissues (N) and metastatic colorectal cancer (T) was purified and RHOXF1 mRNA was quantified by RT-qPCR. Relative
Rhox5 mRNA levels were expressed as normalized to 1.0E6 copies of b-actin mRNA. Bars represent means with s.d. In patient 4, RHOXF1 mRNA
from tumor (T) was below the level of detection.
Table 2 Summary of locations of key data from various cells
Primary Cells or Cell Lines RT-PCR Bisulfite Sequencing ChIP Assay
ES Cells Fig. 1 Fig. 4 Fig. 3
Sertoli cells (TM4) Fig. 1 Fig. 4 Fig. 3
Mononucleocytes (MNC) Fig. 1 Fig. 4 Fig. 3
CT26 (colon cancer) Fig. 1 Fig. 4 Fig. 3
MC38 (colon cancer) Fig. 1 Fig. 4 Fig. 3
4T1 (mammary cancer) Fig. 1 Fig. 4 AF. 1
EMT6 (mammary cancer) Fig. 1 Fig. 4 Fig. 3; Fig. 5
P815 cells (mastocytoma) Fig. 4 AF. 2 Fig. 5; AF. 1
EMT6 & P815 cells treated with epigenetic drugs Fig. 4 n.d. Fig. 5
F9 (embryonic carcinoma) Fig. 1; Fig. 5 n.d. Fig. 5
MOSEC (ovarian cancer) Fig. 1; Fig. 6 Fig. 4 Fig. 3
MOSEC SP Fig. 6 n.d. Fig. 6
n.d., not done. AF: Additional File.
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Upon induced differentiation by either drug, K27me3
disappeared and K4me2 was reduced (p < 0.05), while
K9me2 was not significantly affected.
Rhox5 induction in silenced cancer cells by epigenetic
drugs via increased permissive and decreased repressive
marks
We sought to study the dynamic changes of histone
marks along with Rhox5 gene induction in cancer cells
treated with DAC or MS-275. CA07/A, EMT6 and P815
cancer cells express very low levels of Rhox5 mRNA
(Figure 1 and Table 1). Upon treatment with decitabine
(DAC) or MS-275, Rhox5 mRNA was significantly upre-
gulated, ranging from 40 to 3000-fold (Figure 5C). We
then analyzed the histone marks in the Pd in cancer
cells without or with drug treatment (Figure 5D). In
mock-treated EMT6 and P815 cancer cells, there were
elevated levels of H3K9me2, very low levels of
H3K27me3, and undetectable levels of H3K4me2. After
drug treatment, significant induction in H3K4me2 and
reduction in H3K9me2 was observed, yet H3K27me3
remained low or reduced.
Rhox5 was expressed in SP and NSP of cancer cells with
bivalent histone marks
We next examined whether Rhox5 was expressed in
cancer stem (CS)/progenitor cells and whether there
was an associated bivalent chromatin pattern. The SP
from primary cancers and cancer cell lines has been
shown to be enriched for CS/progenitor cells [59].
Hoechst 33342 dye exclusion was performed with vera-
pamil as a specific inhibitor of H33342 transport in
order to identify SP. We initially chose CT26 colorectal
Figure 3 Rhox5 is bivalent marked in ES cells, somatic cells and cancer cells. (A). Histone methylation marks (H3K4me2; H3K27me3 and
H3K9me2) on Rhox5 promoter regions were determined by ChIP assays. Locations of ChIP-1 and ChIP-2 regions were illustrated in the cartoon
of Fig. 1A. (B). Histone acetylation and methylation marks on promoter regions in cancer cells with Rhox5 expression at high (CT26) and low
(EMT6) levels. (C). Quantification of the data from CT26 and EMT6 cells. Bars are mean with s.d.
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of SP (~1%) and that Rhox5 was expressed in both SP
and NSP (data not shown). Due to the number of SP
cells needed to properly perform the ChIP assays, it was
difficult to obtain sufficient SP cells from this colorectal
cancer cell line. Thus we utilized ovarian cancer cells
because ovarian cancer cells contain a relatively large SP
that is enriched for CS/progenitor cells [60]. Indeed we
showed that the MOSEC ovarian cancer cell line con-
tained 9.7% of SP and that this population could be
blocked by verapamil (Figure 6A). RT-qPCR demon-
strated that SP expressed Rhox5 mRNA about 3-fold
higher than NSP from MOSEC cancer cells (Figure 6B).
We examined the possibility of Rhox5 upregulation in
SP by the epigenetic drug MS-275. There was a 3~4-
fold induction of Rhox5 mRNA in both the original
MOSEC and NSP cells by MS-275. However, there was
no significant up-regulation of Rhox5 in MS-275-treated
SP cells (Figure 6B). We also examined two key histone
marks (K4me2 and K27me3, the bivalent marks) and
found that the Pd promoter was marked by both K4me2
a n dK 2 7 m e 3i nb o t hS Pa n dN S Pf r o mM O S E Cc e l l s .
As expected, MS-275 treatment did little to change the
p a t t e r no ft h e s et w oh i s t o n ee p i g e n e t i cm a r k si nS P
cells (Figure 6C).
Rhox5 knockdown attenuated cell proliferation and cell
migration in vitro and tumor growth in vivo
Little is known concerning Rhox5 function in cancer
cells. Therefore we wished to explore the functions of
Rhox5 in cancer cells. We selected a colon cancer model
(CT26) for Rhox5 functional analyses since our initial
Figure 4 Promoter DNA methylation pattern and Rhox5 mRNA expression level. (A). DNA methylation status in Pd, Pp, and TSS regions in
different cell types including ES, somatic cells, and cancer cells. Each column represented one CpG site and one row indicated separate clones
picked for sequencing. Open and filled circles indicate individual unmethylated and methylated CpGs, respectively. (B). Correlation of Pd DNA
methylation status versus gene transcription in 10 different cell types. Cell types are, NE: normal mammary epithelial cells MM3MG. Six cancer
cell lines used are, EMT6, 4T1, P815, MOSEC, CT26 and MC38. -: non-detectable; +/-: extremely low; +: low; ++: moderate; +++: high.
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Rhox5 mRNA.
We used lentivirus-mediated shRNA against Rhox5 to
knockdown the expression of this gene. As shown in
Figure 7A, shRNA clone 49 demonstrated a higher
knockdown efficiency than clone 48 (80% versus 50%) as
determined by RT-qPCR. Western blot analysis con-
firmed that Rhox5 protein was greatly reduced in clone
49 (Figure 7B). We chose clone 49 for further character-
ization in vitro and in vivo . Cell proliferation was signif-
icantly decreased at 72 and 96 h following knockdown
compared to the parental CT26 cells and corresponding
control lentiviral vector transduced (CTV) CT26 cells (p
< 0.05) (Figure 7C). Cell migration ability in clone 49
cells was also significantly reduced (p < 0.05; compared
to CT26 and CTV, respectively) (Figure 7D). We further
examined the property of tumor growth from shRNA
knockdown and parental CT26 cells in a subcutaneous
tumor model in athymic nude mice. Tumor growth was
slower over time in mice inoculated with clone 49 com-
pared to those with parental CT26 cancer cells or CTV
CT26 cells. At the time of sacrifice (day 19), both tumor
volumes and tumor weights were significantly reduced
in the clone 49 group compared to the two control
groups (p < 0.05) (Figure 7E).
Discussion
The Rhox gene cluster is essential for development, and
three members (Rhox2, Rhox4 and Rhox5 ) have impor-
tant functions for pluripotency of ES cells. In a recent
study, it has been demonstrated that Rhox2 and Rhox4
genes, both expressed at low levels in ES cells, are
marked by neither K4 nor K27 trimethylation of histone
H3 in ES cells [61]. This suggests that DNA methylation
is one of the major repressive mechanisms for those
genes that lack both H3 K4/K27 trimethylations. Pre-
vious studies suggest that DNA methylation is involved
in Rhox5 gene regulation, yet histone modifications
Figure 5 Upregulation of Rhox5 mRNA was associated with dynamic changes of H3K4 and H3K27 methylation marks in Pd region. (A).
Upregulation of Rhox5 in differentiating F9 cells as induced by MS-275, RA or RA plus cAMP. The mRNA was quantified by RT-qPCR, and the
level of Rhox5 mRNA in mock-treated was arbitrarily set as 1.0. (B). Occupancy of H3 K4me2, K27me3, and K9me2 marks in Pd region in mock,
MS-275, and RA-treated F9 cells as determined by real-time RT-PCR. (C). Upregulation of Rhox5 mRNA in DAC or MS-275-treated cancer cells.
Fold change of Rhox5 mRNA (as normalized by Gapdh ) was compared to mock-treated cells. (D). ChIP analysis of K4me2, K27me3 and K9me2
marks at Rhox5 Pd region (ChIP-1) in mock and epigenetic drug-treated EMT6 and P815 cancer cells.
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to gene expression have not been examined.
In this study, we undertook the task of analyzing the
epigenetic marks in the Rhox5 gene promoter region,
and we related these modifications to Rhox5 expression
levels in ES cells, germline-tissue-derived Sertoli cells,
cancer cells, and cancer stem/progenitor cells, as well as
Rhox5 -silenced somatic cells. We had three main goals
in mind. First, we wanted to examine both DNA methy-
lation patterns and histone marks around the promoter
region to determine if the epigenetic patterns would
correlate with Rhox5 expression in those cells. Second,
we wish to examine whether the “bivalent domain” epi-
genetic feature originally identified in key developmental
genes in ES cells also existed in the Rhox5 gene in both
ES cells and other types of cells such as cancer stem
cells. Finally, since Rhox5 is expressed in most, if not all,
of the cancer cell lines and in colorectal cancer in vivo,
it was of great interest to begin to uncover its potential
function in cancer.
The general conclusion from our current study is that
the sum of both active and repressive epigenetic marks
together dictates the levels of Rhox5 mRNA expression
in a particular cell type or cell line. DNA hypermethyla-
tion together with repressive histone modifications dic-
tate the silencing or extreme reduction in Rhox5
expression in normal mononucleocytes (MNC) or
EMT6 cancer cells. In cells expressing low levels of
Rhox5 such as ES cells, F9 cells, and TM4 cells, DNA is
moderately methylated, and the histone epigenetic
marks profile shifted to a more neutral state. These cells
displayed both active marks and repressive marks, even
though the exact marks and levels of these marks varied
from one cell type to another. The existence of a “biva-
lent domain” represents such an epigenetic feature in
these cells. In cells (CT26 and MC38) with high levels
Figure 6 Rhox5 mRNA expression and K4 and K27 bivalent marks in mock or MS-275 treated SP and NSP cells. (A). Existence of SP and
NSP in MOSEC cancer cells. (B). Regulation of Rhox5 mRNA expression in mock or MS-275-treated MOSEC, SP, and NSP cells. *: P < 0.05. (C).
Occupancy of K4 and K27 marks on the chromatin of Pd ChIP-1 region in SP, NSP, and MS-275-treated SP cells. Experiments were performed in
triplicate; error bars depict SEM.
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active histone marks are also elevated, consistent with
high levels of Rhox5 mRNA. Surprisingly, we also
detected high levels of repressive histone marks.
We found the “bivalent domain” chromatin epigenetic
structure in the Rhox5 promoter not only in ES cells
and SP cells enriched for cancer stem/progenitor cells,
but also in cancer cells and fully differentiated germline
tissue-derived somatic Sertoli cells. Our study is not the
first to show that the bivalent chromatin signature is
present in somatic cells. Roh et al. have shown that
about 59% of gene promoters studied in primary human
T cells contain bivalent marks [62]. In the human fore-
skin fibroblast BJ cell line, bivalent marks exist in some
lineage specific genes [63]. In cancer cells, SFRP and
GATA genes are marked by a bivalent chromatin
domain, and the authors defined this as a “stem cell-like
chromatin structure” [60]. For Rhox5, we also found this
Figure 7 ShRNA-mediated knockdown of Rhox5 reduced cell migration and attenuated growth of CT26 cancer cells. (A). Efficiency of
Rhox5 knockdown of shRNA clones with different target sequences against Rhox5. Lentiviral particles with control empty vector (CTV) or 2
different target sets (clone 48, 49) of shRNA were used to infect CT26 cells. After 3
rd round of puromycin selection, total RNA was purified and
analyzed with RT-qPCR and expression of relative Rhox5 mRNA was compared to the empty vector control (set as 1.0). (B). Reduced Rhox5
protein level in Rhox5 shRNA-treated clone 49 cells. Representative result of Western blot film exposed for a short time (10 seconds) was shown.
Rhox5 protein in clone 49 was detected in a longer exposure. (C). Proliferation of CT26 cells stably-transfected with control or targeted shRNA at
different time points in vitro. (D). Migration ability of CT26 cells stably-transfected with control or targeted shRNA. (E). Tumor volumes (left side)
and tumor weight (right side) of control and targeted shRNA stably-transfected CT26 cells at day 19 after inoculation in athymic nude mice. *: p
< 0.05 when compared with control groups.
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lines (CT26, MC38 and MOSEC). Populations of cancer
cells are heterogeneous and contain only a small num-
ber of cancer stem cells that possess the capacity to
maintain self-renewal and undifferentiated status. We
further sorted two cell populations (SP and NSP) from
MOSEC cells. Surprisingly, both fractions of cells con-
tain the bivalent domain in the Rhox5 gene promoter.
One of our initial aims was to induce differentiation of
CS/progenitor cells by HDAC inhibitors [64], in order to
examine Rhox5 gene expression during differentiation
and to explore this as a potential therapeutic approach.
F9 EC cells are considered by many to be the malignant
stem cells of teratocarcinoma [65]. We have confirmed
that F9 cells can be differentiated into “normal cells” by
epigenetic drugs such as RA and MS-275. Upon such an
induction of differentiation these cells display a benign
phenotype as the tumor formation in nude mice was
retarded. The Rhox5 gene was upregulated and the biva-
lent marks disappeared or were greatly reduced. This is
consistent with findings by other investigators that a
fairly large group of active genes contain neither of the
two histone marks [40,66]. The remodeling of these his-
tone marks in the promoter may be related to the differ-
entiation status and/or particular cell type after
induction of differentiation.
When MS-275 was applied to the CS/progenitor-
enriched SP cells from MOSEC ovarian cancer, it failed
to up-regulate Rhox5 and did not reduce the bivalent
chromatin pattern in the gene. In this and other studies,
SP cells were isolated based on the property of high
levels of ABCG2 pump molecule capable of mediating
the active efflux of numerous anticancer drugs and the
dye Hoechst [59]. These SP cells could mediate the
efflux of MS-275 similar to what occurs with other
drugs. This might explain why SP cells failed to respond
to MS-275-induced cell differentiation.
We showed that Rhox5 knockdown by shRNA in
CT26 colon cancer decreased cell migration and cell
proliferation in vitro and tumor growth in vivo .T h i si s
reminiscent of the previous results that targeted disrup-
tion of Rhox5 increased male germ cell apoptosis and
reduced sperm production, sperm motility, and fertility
[12]. What are the downstream molecules and how does
Rhox5 knockdown affect downstream signaling in can-
cer? One gene directly targeted by Rhox5 is Unc5c,a
tumor suppressor frequently silenced by DNA methyla-
tion in colon cancer [21,67]. In CT26 colon cancer cells,
Unc5c is not expressed, and Rhox5 knockdown by
shRNA did not change Unc5c expression (data not
shown). Instead, the attenuated CT26 cancer growth
and migration by Rhox5 knockdown may be mediated
by Ras-ERK signaling pathway. Evidence for this could
be found in a colon adenoma model induced by
conditional activation of K-ras
V12 in Msh2 knockout
mice in which Rhox5 is one of three genes significantly
upregulated [17]. Interestingly, P1A, another epigeneti-
cally regulated and X-linked cancer-germline gene we
have studied previously [35], was also upregulated in
this K-ras
V12 /Cre//Msh2
- tumor model. A recent study
showed that ectopic expression of Rhox5 in cancer cells
induced a significantly increased extracellular signal-
regulated kinase (ERK) activity and multiple resistance
to various apoptotic pressures [23]. In addition, it has
been shown that Ras signaling activates Rhox5 transcrip-
tion through its Pd promoter [68]. Oncogenic Ras sig-
naling also induces tumor promoting genes and directs
epigenetic inactivation of tumor suppressor genes
[69,70]. Another downstream component of the Ras sig-
naling pathway, NF-B, promotes breast cancer cell
migration and thus metastasis by inducing chemokine
receptor CXCR4 [71]. Therefore, our finding that Rhox5
knockdown attenuated tumor cell growth and cell
migration fits a hypothetic Ras tumor promoting signal-
ing pathway in which ERK1/2, NF-B, and Rhox5 func-
tion downstream. Further studies will shed more light
on Rhox5 function in precancerous lesions and in can-
cer progression of colon malignancy. In addition, Rhox5
is widely expressed in cancer cells and cancer stem/pro-
genitor cells, and can be selectively induced or sup-
pressed by epigenetic agents. Thus, Rhox5 could serve
as an ideal target for therapeutic interventions including
shRNA therapy, cancer immunotherapy, and epigenetic
therapy.
The closely related human gene RHOXF1 has been
shown to be expressed in ES cells and adult germline
stem cells, some established cancer lines and in primary
metastatic colorectal cancer. Its expression pattern is
consistent with potential roles in ES cells, adult tissue
stem cells, and possibly cancer stem cells, despite the
fact that we know little, if any, of its biological func-
tions. Efforts to elucidate the functions of RHOXF1 in
the biology of cancer and reproduction and to explore
RHOXF1 as a potential therapeutic target should be
undertaken.
Methods
Cell culture and human tissues
Many cancer cell lines have been used in our previous
studies [15,35]. The F9 EC cells were obtained from the
American Type Culture Collection (Manassas, VA). In
order to maintain F9 undifferentiated status, F9 cells
were grown on gelatin-coated tissue culture plates. All
cells were cultured in the recommended culture media
supplemented with 5% or 10% fetal bovine serum (FBS),
plus penicillin and streptomycin.
Undifferentiated mouse ES cells (genotype 129*129,
passage 18) were purchased from Open Biosystems
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gene expression, bisulfite sequencing, and ChIP assays.
The specimens of human colorectal cancer and
matched normal tissues were collected under the UPCI
protocol # 02-077, with consent of the patients.
Flow cytometry
To identify and isolate the side population and non-side
population cell fractions, cancer cells were harvested,
washed, and suspended at 1.0E6 cells/ml in Hanks
balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA)
as described [72]. The cells were labeled with Hoechst
33342 (Invitrogen) at a concentration of 5.0 μg/ml in
the absence and presence of 50 μM verapamil (Sigma,
S t .L o u i s ,M O ) .T h el a b e l e dc e l l sw e r ei n c u b a t e df o r9 0
min at 37°C. After washing with HBSS once, the cells
were counterstained with 1.0 μg/ml 7-AAD (Becton
Dickinson, Franklin Lakes, NJ) to label dead cells. The
cells were analyzed by using a MoFlo cell sorter (Beck-
man Coulter, Fort Collins, CO).
Drug treatment
Rhox5 gene induction was performed by treating can-
cer cells with 5-aza-2-deoxycytidine (DAC, 2.0 μMf o r
48 h) or MS-275 (2.0 μM for 72 h) [15]. Cells were
plated in 100 mm culture plates to obtain ~20% con-
fluence. After overnight incubation, cells were treated
daily with drugs at different concentrations for 48 ~
72 h. To induce differentiation, F9 cells were cultured
in gelatinized plates in the presence of 0.1 μMr e t i n o i c
acid (RA) (Sigma) or RA plus 1.0 mM cAMP (Sigma)
as described [8].
RNA isolation, RT-PCR and RT-qPCR
Total RNA purification, RT-PCR, and RT-qPCR were
performed as described previously [15]. RT-qPCR was
performed with an ABI StepOnePlus real-time PCR sys-
tem (Applied Biosystems, Foster City, CA). The copy
numbers of mRNA were determined with relative quan-
titation by the comparative Ct method using the soft-
ware with the machine.
Western blot analysis
Western blot analysis was performed as described [15].
Briefly, protein extract was prepared from tumor cells
and from ovary and testis tissues of BALB/c mice.
Twenty micrograms of protein was resolved on 12%
SDS polyacrylamide gels and transferred to immobilon-
P PVDF membrane (Millipore, Billerica, MA). The
resulting blots were blocked with 5% nonfat dry milk
and probed with antibodies specific for Rhox5 (Abcam,
Cambridge, MA) and ß-actin (Sigma).
Isolation of genomic DNA and bisulfite sequencing
Genomic DNA from cell lines was extracted using a
QIAamp DNA mini kit (Qiagen, Volencia, CA). DNA
from spleen mononucleocytes (MNC) of a BALB/c
mouse was extracted using a DNeasy Tissue kit (Qia-
gen). Bisulfite modification of DNA, subcloning, and
sequencing of converted DNA were performed as
described [15].
Chromatin immunoprecipitation (ChIP) assay and real-
time PCR
ChIP assays were performed using EZ-ChIP kits (Milli-
p o r e ,B i l l e r i c a ,M A )[ 1 5 ] .T h ef o l l o w i n gC h I P - g r a d e
antibodies were used: anti-acetyl histone H3 [H3ac] and
anti-acetyl histone H4 [H4ac] (Millipore), anti-acetyl
histone H3 lysine 9 [H3K9ac], anti-dimethyl histone H3
lysine 4 [H3K4me2], anti-dimethyl histone H3 lysine 9
[H3K9me2], anti-trimethyl histone H3 lysine 27
[H3K27me3], and an isotype control IgG (All from
Abcam). In earlier experiments, histone 3 K4, K27, and
K9 methylation in the ChIP-1 region was quantified by
semi-quantitative PCR gel density analysis. In all later
experiments, real-time PCR was used to quantify the
amounts of DNA fragment in the ChIP assays. Specific
primer sets were designed to amplify Rhox5 gene ChIP-
1 (Pd) and ChIP-2 (Pp) regions. Most primer sequences
are listed in Additional File 4. For Rhox5 Pd real-time
PCR, 2.0 μl of DNA was added to PCR reaction systems
using a QuantiTect SYBR Green PCR kit (Qiagen). We
performed quantitative PCR data analysis of ChIP assay
using a formula described in the User Manual of Cham-
pionChIP™ kits (SA Biosciences, Frederick, MD, USA).
Briefly, we normalized each ChIP DNA fractions’ Ct
value to the Input DNA fraction Ct value for the same
qPCR Assay (ΔCt) to account for chromatin sample pre-
paration differences. Then we reported ChIP-qPCR
results as a “%I n p u t ” for characterizing individual
experimental samples.
ShRNA-mediated knockdown of Rhox5 gene
Four different lentivirus particles with target shRNA
against Rhox5 were ordered from Sigma. The best result
for knockdown was obtained from clone 49. The shRNA
clone 48 sequence is, CCGGAGTGCAGAATTGGTT-
TAAGATCTCGAGATCTTAAACCAATTCTG-
CACTTTTTTG. The shRNA clone 49 sequence is,
CCGGCAGCGCACTAATTCCTTTGATCTCGAGAT-
CAAAGGAATTAGTGCGCTGTTTTTG). A lentivirus
with the corresponding empty plasmid vector (CTV)
w a su s e da sn o n - t a r g e tc o n t r o l .L e n t i v i r u sw i t hRhox5
target and non target shRNA was used to infect CT26
cells at MOI of 1.0. After three rounds of puromycin
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selected and Rhox5 knockdown was assessed by both
real-time RT-PCR and Western blot analysis.
Cell proliferation and cell migration assays
For cell proliferation assays, 1,000 CT26 cancer cells in
10% FBS-containing DMEM medium were added to
each well of a 96-well plate. Cell proliferation was deter-
mined by using CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay Kit (Promega, Madison, WI).
The reagent was added directly to culture wells, and fol-
lowing incubation for 4 h at 37°C, absorbance at 490
nm was measured using a 96-well plate reader. For
trans-well migration assays, 1 × 10
5 serum starved cells
in serum-free medium were added to the top chambers
of 24-well trans-well plates (Cell Biolabs, San Diego,
CA), and growth media containing 10% FBS was added
to the bottom chambers. After 12 h of incubation,
migrating cells were stained, and absorbance was
recorded at 560 nm. Assays were done in triplicates,
and the data are presented as the average absorbance of
cells.
In vivo tumor growth
Athymic nude mice were ordered from Tacomic Farms,
Inc. (Germantown, NY). Mice were housed in standard
conditions and given food and water ad libitum .T h e
animal study was approved by the Institutional Animal
Care and Use Committee of the University of
Pittsburgh.
Rhox5 and control shRNA lentivirus-stably-transduced
CT26 colon cancer cells were injected subcutaneously
into hind frank of 5-6 weeks old athymic nude mice
(1.0E5 cells per mouse, 5 mice per group). Mice were
closely monitored until any one animal possessed a
tumor of 2.0 centimeter in diameter. At this time point,
tumor volumes of all mice were measured, and mice
were sacrificed.
Statistical analysis
Statistical analysis was calculated using Microsoft Excel
or SPSS software. Significance was calculated using Stu-
dent’s t -test.
Additional material
Additional file 1: The results of ChIP assays with Rhox5 promoter
regions in MM3MG, P815 and 4T1 cells. The ChIP assays were
performed as those in Figure 2. Shown are one mammary fibloblast
(MM3MG) and two cancer cell lines.
Additional file 2: DNA methylation analysis in ChIP-1 and ChIP-2
regions of the gene from MM3MG mammary epithelial cells and
P815 cancer cells. Data of DNA methylation analysis in Rhox5 ChIP-1
and ChIP-2 regions are presented. The details are in Figure 3.
Additional file 3: Growth of F9 embryonic carcinoma in nude mice.
Tumor growth in nude mice, inoculated with mock-treated F9 cells (left
frank) or MS-275-treated F9 cells (right frank).
Additional file 4: PCR primers used for PCR assays.
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